Clinical Trials/NCT00562055

NCT00562055

Withdrawn

Phase 2

Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Pfizer0 sitesNovember 2007

ConditionsAttention Deficit Hyperactivity Disorder

InterventionsPNU-165442G; [S,S]-reboxetine Atomoxetine

DrugsAtomoxetine PNU-165442G; [S,S]-reboxetine

Overview

Phase: Phase 2
Intervention: PNU-165442G; [S,S]-reboxetine
Conditions: Attention Deficit Hyperactivity Disorder
Sponsor: Pfizer
Primary Endpoint: Adult ADHD Investigator Symptom Rating Scale - Total Score
Status: Withdrawn
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This study will compare the safety and efficacy of [S,S]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.

Registry

clinicaltrials.gov

Start Date

November 2007

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Pfizer

Eligibility Criteria

Inclusion Criteria

•Diagnosis of Attention Deficit Hyperactivity Disorder according to DSM-IV criteria.
•Score of 24 or higher on the Adult ADHD Investigator Symptom Rating Scale
•Score of 4 or higher on the Clinician Global Impression - Severity scale

Exclusion Criteria

•Significant comorbid psychiatric diagnoses
•Significant risk of suicidal or violent behavior

Arms & Interventions

Arm A

Intervention: PNU-165442G; [S,S]-reboxetine

Arm B

Intervention: Atomoxetine

Outcomes

Primary Outcomes

Adult ADHD Investigator Symptom Rating Scale - Total Score

Time Frame: 4 weeks

Secondary Outcomes

Adult ADHD Investigator Symptom Rating Scale - Hyperactivity/Impulsivity Subscale Score(4 weeks)
Adult ADHD Investigator Symptom Rating Scale - Inattention Subscale Score(4 weeks)

Similar Trials

Completed

Phase 2

Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety DisorderGeneralized Social Phobia

NCT00260533University of California, San Diego27

Completed

Phase 3

Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant TherapyAttention Deficit Hyperactivity Disorder

NCT00485550Eli Lilly and Company14

Completed

Phase 2

A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With FibromyalgiaPain

NCT00357825Pfizer246

Completed

Phase 4

Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)Attention Deficit Hyperactivity DisorderReading Disorder

NCT00191906Eli Lilly and Company121

Completed

Phase 2

Effects of Atomoxetine in Mild Cognitive ImpairmentMild Cognitive Impairment

NCT01522404Emory University39